Literature DB >> 11240157

Motor control of airway goblet cells and glands.

D F Rogers1.   

Abstract

Activation of nerves increases airway mucus secretion. The mucus derives from submucosal glands and epithelial goblet cells. Depending upon species and airway level, innervation comprises parasympathetic (cholinergic), sympathetic (adrenergic) and 'sensory-efferent' pathways. In all species studied, cholinergic mechanisms predominate, particularly in human airways. Muscarinic M3 receptors on the secretory cells mediate the cholinergic response. Tachykinins (substance P and neurokinin A) mediate the sensory-efferent response, acting via tachykinin NK1 receptors. Endogenous mechanisms regulate the magnitude of neurogenic secretion, including enzymes (degrade neurotransmitters), nitric oxide (NO) and vasoactive intestinal peptide (VIP) (regulate stimulated secretion), and muscarinic M2 autoreceptors (inhibit acetylcholine release). Exogenous opioids also inhibit neurogenic secretion prejunctionally. Both VIP and opioids act by opening large conductance, calcium-activated potassium (BK(Ca)) channels. Present understanding of neural control of mucus secretion in animal airways requires translation into human data. This information should lead to rational development of drugs for bronchial diseases in which neurogenic mucus hypersecretion contributes to pathophysiology, including chronic bronchitis and asthma.

Entities:  

Mesh:

Year:  2001        PMID: 11240157     DOI: 10.1016/s0034-5687(00)00209-7

Source DB:  PubMed          Journal:  Respir Physiol        ISSN: 0034-5687


  32 in total

1.  Cleavage at the furin consensus sequence RAR/KR(109) and presence of the intervening peptide of the respiratory syncytial virus fusion protein are dispensable for virus replication in cell culture.

Authors:  Gert Zimmer; Karl-Klaus Conzelmann; Georg Herrler
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 2.  The role of vagal afferent nerves in chronic obstructive pulmonary disease.

Authors:  Bradley J Undem; Marian Kollarik
Journal:  Proc Am Thorac Soc       Date:  2005

Review 3.  Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.

Authors:  Martin S Steinhoff; Bengt von Mentzer; Pierangelo Geppetti; Charalabos Pothoulakis; Nigel W Bunnett
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

4.  Effect of the long-acting tachykinin NK(1) receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets.

Authors:  S Khan; Y C Liu; A M Khawaja; S Manzini; D F Rogers
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

5.  Runx2, a novel regulator for goblet cell differentiation and asthma development.

Authors:  Ning Shi; Jing Zhang; Shi-You Chen
Journal:  FASEB J       Date:  2016-10-17       Impact factor: 5.191

6.  Signaling pathways used by EGF to stimulate conjunctival goblet cell secretion.

Authors:  Robin R Hodges; Jeffrey A Bair; Richard B Carozza; Dayu Li; Marie A Shatos; Darlene A Dartt
Journal:  Exp Eye Res       Date:  2012-09-04       Impact factor: 3.467

Review 7.  Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases.

Authors:  Khuder Alagha; Alain Palot; Tunde Sofalvi; Laurie Pahus; Marion Gouitaa; Celine Tummino; Stephanie Martinez; Denis Charpin; Arnaud Bourdin; Pascal Chanez
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

Review 8.  Liquid secretion properties of airway submucosal glands.

Authors:  Stephen T Ballard; Sarah K Inglis
Journal:  J Physiol       Date:  2003-12-05       Impact factor: 5.182

9.  Modulation of Ca2+ oscillation and melatonin secretion by BKCa channel activity in rat pinealocytes.

Authors:  Hiroya Mizutani; Hisao Yamamura; Makoto Muramatsu; Yumiko Hagihara; Yoshiaki Suzuki; Yuji Imaizumi
Journal:  Am J Physiol Cell Physiol       Date:  2016-01-20       Impact factor: 4.249

Review 10.  Using guinea pigs in studies relevant to asthma and COPD.

Authors:  Brendan J Canning; Yangling Chou
Journal:  Pulm Pharmacol Ther       Date:  2008-02-02       Impact factor: 3.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.